vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and Paramount Skydance Corporation (PSKY). Click either name above to swap in a different company.
Paramount Skydance Corporation is the larger business by last-quarter revenue ($4.1B vs $2.8B, roughly 1.5× Bausch Health Companies Inc.). Paramount Skydance Corporation runs the higher net margin — -0.3% vs -3.7%, a 3.4% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs -38.8%). Bausch Health Companies Inc. produced more free cash flow last quarter ($403.0M vs $222.0M).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
Paramount Skydance Corporation is an American multinational mass media and entertainment conglomerate. The company is headquartered at the Paramount Pictures lot in the Hollywood neighborhood of Los Angeles, California, with multiple of Paramount's divisions and subsidiaries, as well as one of Paramount's major offices and meeting places, being headquartered at the previous Paramount Global headquarters at One Astor Plaza in New York City.
BHC vs PSKY — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $4.1B |
| Net Profit | $-103.0M | $-13.0M |
| Gross Margin | — | — |
| Operating Margin | 17.0% | 5.9% |
| Net Margin | -3.7% | -0.3% |
| Revenue YoY | 9.3% | -38.8% |
| Net Profit YoY | -205.1% | -1400.0% |
| EPS (diluted) | $-0.30 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | — | ||
| Q3 25 | $2.7B | $4.1B | ||
| Q2 25 | $2.5B | $0 | ||
| Q1 25 | $2.3B | $0 | ||
| Q4 24 | $2.6B | — | ||
| Q3 24 | $2.5B | $6.7B | ||
| Q2 24 | $2.4B | $0 | ||
| Q1 24 | $2.2B | — |
| Q4 25 | $-103.0M | — | ||
| Q3 25 | $179.0M | $-13.0M | ||
| Q2 25 | $148.0M | $0 | ||
| Q1 25 | $-58.0M | $0 | ||
| Q4 24 | $98.0M | — | ||
| Q3 24 | $-85.0M | $1.0M | ||
| Q2 24 | $10.0M | $0 | ||
| Q1 24 | $-64.0M | — |
| Q4 25 | 17.0% | — | ||
| Q3 25 | 23.1% | 5.9% | ||
| Q2 25 | 17.5% | — | ||
| Q1 25 | 12.2% | — | ||
| Q4 24 | 21.8% | — | ||
| Q3 24 | 12.7% | 5.0% | ||
| Q2 24 | 16.2% | — | ||
| Q1 24 | 13.1% | — |
| Q4 25 | -3.7% | — | ||
| Q3 25 | 6.7% | -0.3% | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -2.6% | — | ||
| Q4 24 | 3.8% | — | ||
| Q3 24 | -3.4% | 0.0% | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | -3.0% | — |
| Q4 25 | $-0.30 | — | ||
| Q3 25 | $0.48 | $-0.01 | ||
| Q2 25 | $0.40 | $0.00 | ||
| Q1 25 | $-0.16 | $0.00 | ||
| Q4 24 | $0.24 | — | ||
| Q3 24 | $-0.23 | $0.00 | ||
| Q2 24 | $0.03 | $0.00 | ||
| Q1 24 | $-0.17 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $3.3B |
| Total DebtLower is stronger | $20.8B | $13.3B |
| Stockholders' EquityBook value | $-554.0M | $12.0B |
| Total Assets | $26.4B | $43.2B |
| Debt / EquityLower = less leverage | — | 1.11× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | $3.3B | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $719.0M | — | ||
| Q2 24 | $595.0M | — | ||
| Q1 24 | $733.0M | — |
| Q4 25 | $20.8B | — | ||
| Q3 25 | $21.0B | $13.3B | ||
| Q2 25 | $21.7B | — | ||
| Q1 25 | $21.5B | — | ||
| Q4 24 | $21.6B | — | ||
| Q3 24 | $21.5B | — | ||
| Q2 24 | $21.7B | — | ||
| Q1 24 | $22.1B | — |
| Q4 25 | $-554.0M | — | ||
| Q3 25 | $-565.0M | $12.0B | ||
| Q2 25 | $-764.0M | $0 | ||
| Q1 25 | $-1.2B | $0 | ||
| Q4 24 | $-1.3B | — | ||
| Q3 24 | $-1.2B | $17.1B | ||
| Q2 24 | $-1.2B | $0 | ||
| Q1 24 | $-1.1B | — |
| Q4 25 | $26.4B | — | ||
| Q3 25 | $26.8B | $43.2B | ||
| Q2 25 | $27.3B | $0 | ||
| Q1 25 | $26.4B | $0 | ||
| Q4 24 | $26.5B | — | ||
| Q3 24 | $26.5B | — | ||
| Q2 24 | $26.5B | — | ||
| Q1 24 | $26.9B | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.11× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | $268.0M |
| Free Cash FlowOCF − Capex | $403.0M | $222.0M |
| FCF MarginFCF / Revenue | 14.4% | 5.4% |
| Capex IntensityCapex / Revenue | 3.3% | 1.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $495.0M | — | ||
| Q3 25 | $405.0M | $268.0M | ||
| Q2 25 | $289.0M | $0 | ||
| Q1 25 | $211.0M | $0 | ||
| Q4 24 | $601.0M | — | ||
| Q3 24 | $405.0M | — | ||
| Q2 24 | $380.0M | $0 | ||
| Q1 24 | $211.0M | — |
| Q4 25 | $403.0M | — | ||
| Q3 25 | $314.0M | $222.0M | ||
| Q2 25 | $190.0M | — | ||
| Q1 25 | $96.0M | — | ||
| Q4 24 | $495.0M | — | ||
| Q3 24 | $334.0M | — | ||
| Q2 24 | $302.0M | — | ||
| Q1 24 | $129.0M | — |
| Q4 25 | 14.4% | — | ||
| Q3 25 | 11.7% | 5.4% | ||
| Q2 25 | 7.5% | — | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | 19.3% | — | ||
| Q3 24 | 13.3% | — | ||
| Q2 24 | 12.6% | — | ||
| Q1 24 | 6.0% | — |
| Q4 25 | 3.3% | — | ||
| Q3 25 | 3.4% | 1.1% | ||
| Q2 25 | 3.9% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | 2.8% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 3.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | 2.26× | — | ||
| Q2 25 | 1.95× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.13× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 38.00× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
PSKY
| Affiliate And Subscription | $2.0B | 49% |
| Advertising | $1.3B | 31% |
| Licensing And Other | $775.0M | 19% |
| Related Party | $40.0M | 1% |
| Theatrical | $39.0M | 1% |
